Skip to content

A Study on the Efficacy of Opioid-Sparing Anesthesia Combined with Triple Antiemetic Regimen in Preventing Postoperative Nausea and Vomiting in Female Patients Undergoing Thyroid Surgery

A Study on the Efficacy of Opioid-Sparing Anesthesia Combined with Triple Antiemetic Regimen in Preventing Postoperative Nausea and Vomiting in Female Patients Undergoing Thyroid Surgery

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107369
Enrollment
Unknown
Registered
2025-08-11
Start date
2025-08-11
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting

Interventions

Conventional opioid/oligoopiatic anesthesia observation group:None

Sponsors

The Second Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. American Society of Anesthesiologists (ASA) classification of grade I-II; 2. Female patients aged 18 years or above; 3. Patients scheduled for elective thyroidectomy; 4. Patients planning to receive a triple antiemetic drug regimen (diphenhydramine, palonosetron, dexamethasone) during the operation; 5. Anesthesia methods of general anesthesia or general anesthesia combined with nerve block; 6. Patients and their authorized representatives have agreed to participate in this study and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Those allergic to anesthetic drugs (such as various general anesthetics and local anesthetics); 2. Patients with coagulation disorders; 3. Those with infection at the puncture site, anatomical deformity or tumor invasion; 4. Those who have had persistent nausea and vomiting symptoms within 3 months before the surgery or regularly use antiemetic drugs; 5. Those with contraindications to non-steroidal anti-inflammatory drugs (such as active gastrointestinal ulcers, severe renal dysfunction, aspirin asthma, etc.); 6. Those with severe neurological diseases or cognitive dysfunction that affect communication and pain/PONV assessment before the surgery; 7. Those who refuse to participate in this study; 8. Those who have used drugs that may affect PONV assessment within 24 hours before the surgery (such as opioids, antiemetics, high-dose hormones, etc.); 9. Those with a long-term history of chronic pain and long-term use of opioids; 10. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative nausea and vomiting;Salvage antiemetics use;Postoperative nausea and vomiting severity;

Secondary

MeasureTime frame
Incidence of adverse events (respiratory depression, hyperalgesia, etc.);Restore quality Q15;Patient satisfaction score;Length of hospital stay after surgery;Postoperative opioid dosage;Intraoperative opioid dosage;Time to first require analgesic medication;Postoperative pain score (at rest and when coughing and swallowing);

Countries

China

Contacts

Public ContactLiu Haitao

The Second Hospital of Hebei Medical University

mzlht@sina.com+86 151 3011 9853

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026